Dechra Pharmaceuticals Manufacturing
Dechra Pharmaceuticals Manufacturing is the manufacturing business of Dechra Pharmaceuticals PLC, operating from two European sites at Skipton, UK, Bladel, NL and also Melbourne USA.
Dechra Pharmaceuticals Manufacturing is the manufacturing business of Dechra Pharmaceuticals PLC, operating from two European sites at Skipton, UK, Bladel, NL and also Melbourne USA.
Dechra Pharmaceuticals Manufacturing provides a comprehensive range of contract pharmaceutical services.
Our mission is to provide an excellent service, developing and supplying quality products to our customers worldwide.
Dechra is a complete service provider, offering product development through manufacturing and packing to QP release, supported by highly qualified staff, trained to the highest standard.
Ongoing investment in the factory at Skipton, has created a, well equipped, MHRA and FDA approved cGMP facility that produces a diverse range of dosage forms and wide scale of volumes and batch sizes, including scale-up and commercial batch production. The site comprises multiple manufacturing and packing suites with QC, validation and development laboratories. It also has a 160 pallet CD store.
Dechra's cGMP facility at Bladel, Netherlands is IGZ approved to manufacture, import and pack pharmaceuticals for veterinary use, including controlled drugs.
The Melbourne facility produces tablets and chews for the US veterinary market.
All in all we are, Your Complete Pharmaceutical Service Provider.
Contact:
Dechra Pharmaceuticals Manufacturing
Email: manufacturing.enquiries@dechra.com
Website: www.dechramanufacturing.com
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
